Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses

BACKGROUND: The oral proteasome inhibitor ixazomib has been approved by regulatory authorities around the world, including in the United States and the European Union, for the treatment of patients with multiple myeloma (MM) who have received at least one prior therapy, based on the pivotal phase II...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Neeraj, Yang, Huyuan, Hanley, Michael J., Zhang, Steven, Liu, Rachael, Kumar, Shaji, Richardson, Paul G., Skacel, Tomas, Venkatakrishnan, Karthik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5610674/
https://www.ncbi.nlm.nih.gov/pubmed/28803351
http://dx.doi.org/10.1007/s11523-017-0524-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5610674/
https://www.ncbi.nlm.nih.gov/pubmed/28803351
http://dx.doi.org/10.1007/s11523-017-0524-3

Ejemplares similares